Stability of coagulation factors I and X during collection and subsequent storage of bank blood in ACD-A and CPD solutions

The stability of coagulation factors in stored blood

The complete coagulation profile of citrate phosphate dextrose (CPD) stored blood has been studied during 21 days storage at 4 degrees C. Ten donations were studied at zero, one, seven, 14 and 21 days. One donation contained small clots and was studied separately. Activities of factors I, II, IX, XII or XIII did not deteriorate significantly. Slight, but clinically unimportant deterioration occurred in factors VII, X and XI. There was marked deterioration in activities of factor V, and factor VIII, the levels decreasing from 1.0u/ml at day zero to 0.51 to 0.30 respectively at day 21. The donation which contained small clots had more marked decreases in factors V and VIII from the first day. The general stability of coagulation factors suggests that even massive blood replacement is unlikely to result in clinically significant coagulation defects.

Clinical and experimental studies on adenine, various nucleosides and their analogs in hematology

In red blood cells as well as in platelets there appears to be a decrease in adenine nucleotides during storage under blood bank conditions. This can be decreased by use of anticoagulant preservatives with higher phosphate content than the standard ACD solution, through the addition of adenine and inosine. Maintenance of higher ATP levels appears to be related to longer circulating life span after transfusion into patients in the case of red blood cells but not platelets. Inosine and more alkaline preservative medium also contribute to the maintenance of 2,3-DPG levels in red blood cells, and with it to the maintenance of normal hemoglobin dissociation curves and thus oxygen-carrying capacity. Certain nucleoside analogs may contribute to the preservation of platelets and of whole blood by their platelet-aggregation inhibitory activity. Platelet-aggregation inhibitors may also be useful in preventing thromboembolic episodes with potentially greater safety than anticoagulants.